Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 401–500 of 1,006
Bonté, P.-E., Arribas, Y. A., Merlotti, A., Carrascal, M., Zhang, J. V., Zueva, E., Binder, Z. A., Alanio, C., Goudot, C., & Amigorena, S. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110916 · Cited by 74
Ritterhouse, L. L. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22174 · Cited by 81
“Although TMB is a promising pan-cancer tool, one must use caution when applying TMB broadly across tumor types, because some tumors have been shown to have a better response than would have been predicted based on TMB (eg, renal cell carcinomas), whereas others have a worse response than would have been predicted base…”
MethodThe Role of Immune Checkpoint Blockade in Uveal Melanoma
Wessely, A., Steeb, T., Erdmann, M., Heinzerling, L., Vera, J., Schlaak, M. S., Berking, C., & Heppt, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030879 · Cited by 89
“Similar to other cancer entities that are associated with the exposure to environmental carcinogens such as nonsmall cell lung cancer (NSCLC), Int.”
BackgroundInfluentialPan-Cancer Analysis of Ligand–Receptor Cross-talk in the Tumor Microenvironment
Ghoshdastider, U., Rohatgi, N., Naeini, M. M., Baruah, P., Revkov, E., Guo, Y. A., Rizzetto, S., Wong, A. M. L., Solai, S., Nguyen, T. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2352 · Cited by 94
“, colorectal cancer) inferred PD-L1 cancer cell expression have markedly different response rates to PD-L1/PD-1 checkpoint blockade in clinical trials (34).”
BackgroundInfluentialNEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.223 · Cited by 74
“increased efficacy of immunotherapy, in particular with anti-PD-1/PD-L1 plus anti-CTLA4.(26,27) However, it is important to acknowledge that only indirect measurement of tumor neoantigen load can be achieved through quantification of TMB.”
BackgroundImmunotherapy in endometrial cancer
Mahdi, H., Chelariu-Raicu, A., & Slomovitz, B. M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003675 · Cited by 93
Park, S. E., Park, K., Lee, E., Kim, J., Ahn, J. S., Im, Y., Lee, C., Jung, H., Cho, S. Y., Park, W., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466768 · Cited by 84
Ma, H., Yang, W., Zhang, L., Liu, S., Zhao, M., Zhou, G., Wang, L., Jin, S., Zhang, Z., & Hu, J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0352-y · Cited by 85
Evaluating the impact of age on immune checkpoint therapy biomarkers
Erbe, R., Wang, Z., Wu, S. K., Xiu, J., Zaidi, N., La, J., Tuck, D. P., Fillmore, N. R., Giraldo, N. A., Topper, M. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109599 · Cited by 84
“Due to the widespread use of TMB as a primary clinical biomarker of ICB therapy (Yarchoan et al., 2017; Goodman et al., 2017), we first examine the relationship of TMB with patient age.”
Self-citationDNA methylation in lung cancer patients: Opening a "window of life" under precision medicine
Liang, R., Li, X., Li, W., Zhu, X. M., & Li, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112202 · Cited by 84
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli, F., & Fumet, J.-D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01816 · Cited by 84
“There is evidence that tumor-specific T cells targeting neoantigens play a role in tumor control (13, 14, 29, 31), but in most tumor types antigen specificities are unknown.”
BackgroundRitch, E. J., Fu, S. Y. F., Herberts, C., Wang, G., Warner, E. W., Schönlau, E., Taavitsainen, S., Murtha, A. J., Vandekerkhove, G. R., Beja, K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1623 · Cited by 78
“Predicting patient response to immune checkpoint inhibitors is complex and multifactorial (7), but high TMB is consistently linked with improved response rates (8, 9).”
BackgroundDriscoll, C. B., Schuelke, M. R., Kottke, T. J., Thompson, J., Wongthida, P., Tonne, J. M., Huff, A. L., Miller, A. C., Shim, K. G., Molan, A. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14568-7 · Cited by 86
Kang, D. H., Park, C., Chung, C., Oh, I., Kim, Y., Park, D., Kim, J., Kwon, G. C., Kwon, I., Sun, P., et al. (2020) · Immune Network · doi:10.4110/in.2020.20.e27 · Cited by 87
“The TMB is a tumor intrinsic feature-related biomarker, and several studies have shown that it significantly correlates with the ORR and survival of ICI treatment, regardless of PD-L1 expression (22,23).”
BackgroundKhan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 83
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
Lee, J. V., Housley, F., Yau, C. S. F., Nakagawa, R. M., Winkler, J., Anttila, J. M., Munne, P., Savelius, M., Houlahan, K. E., de Mark, D. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31238-y · Cited by 86
Nanovaccines: An effective therapeutic approach for cancer therapy
Gurunathan, S., Pratheep, T., Wang, L., Cao, Q., & Kim, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115992 · Cited by 89
Evangelista, L., Cuppari, L., Menis, J., Bonanno, L., Reccia, P., Frega, S., & Pasello, G. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001025 · Cited by 79
Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing
Zhang, L., & Zhang, Z. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0658 · Cited by 79
“Cancer immunotherapies, such as immune-checkpoint blockade, are clinically effective formultiple cancer indications, such as melanoma and non–small cell lung cancer, although the clinical benefit is not uniform (1, 2), and T cells have been a focal point in these immunotherapies.”
BackgroundTsung, I., Worden, F. P., & Fontana, R. J. (2020) · The Oncologist · doi:10.1002/onco.13539 · Cited by 80
“Studies have correlated high TMB with better tumor response rates from ICI treatment [11].”
BackgroundThe right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Kwon, M., Jung, H., Nam, G., & Kim, I.-S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.009 · Cited by 78
CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis
Ye, W., Luo, C., Liu, F., Liu, Z., & Chen, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.634617 · Cited by 89
“Despite the significances of these correlations, the correlation coefficients between CD96 and TMB, as well as MSI, were below 0.6 in almost all cancers, suggesting that CD96 was rather unlikely to affect tumorigenesis Frontiers in Oncology | www.frontiersin.org 7 by participating in the process of genetic alterations…”
BackgroundInfluentialZheng, H., Liu, H., Li, H., Dou, W., & Wang, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.744677 · Cited by 83
“Tumor mutation burden (TMB) has been proposed as an immunotherapy efficacy predictor (Yarchoan et al., 2017),”
BackgroundLiu, J., Chen, C., Wang, Y., Qian, C., Wei, J., Xing, Y., & Bai, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746647 · Cited by 96
“Positive response to immunotherapy usually depends on tumor cell interactions (27, 28) and immune regulation within tumor microenvironment (TME) (29, 30).”
BackgroundComputational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 86
“A high TMB has been associated with responsiveness to ICIs 21,22,29,51–54 ; for example, cutaneous melanomas tend to have a high TMB owing to the powerful mutagenic effects of UV radiation 55 and patients with this malignancy often have good responses to ICIs 24,56,57 .”
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Zhang, X., Wang, Y., A, G., Qu, C., & Chen, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.721030 · Cited by 76
“TMB is used to reflect the number of mutations within tumor cells and is a quantifiable biomarker, which is the latest for evaluating the therapeutic effect of PD-1 antibodies (13).”
MethodPancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
Li, K., Yuan, J., Trafton, D., Wang, J., Niu, N., Yuan, C., Liu, X., & Zheng, L. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.01.002 · Cited by 81
“PDAC bears low-moderate mutational burden and has lower immunogenic potential.(3) The TME of PDAC has increased the infiltration of immunosuppressive cells, like MDSCs and Treg cells, and is characterized by increased infiltration of carcinoma associated fibroblasts (CAFs) resulting in collagen deposition with an elev…”
BackgroundDelyon, J., Biard, L., Renaud, M., Resche‐Rigon, M., LeGoff, J., Dalle, S., Heidelberger, V., Meda, L. D., Toullec, L., Carcelain, G., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00097-3 · Cited by 78
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
“Although many exceptions have emerged, there is a correlation between the mutational load and prediction for a given tumor type to respond to anti-PD-1/PD-L1.(39) Recent studies show that the mutational load in the tumor is correlated with the response to pembrolizumab monotherapy in patients with NSCLC expressing PD-…”
BackgroundXiao, W., Du, N., Huang, T., Guo, J., Mo, X., Yuan, T., Chen, Y., Ye, T., Xu, C., Wang, W., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.019 · Cited by 80
“As for TMB, median TMB is associated with the objective response rate of ICBs among 27 tumor types [22].”
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 78
“The genomic alterations occurring in tumor cells display the capacity to generate tumor-specific antigens (neoantigens), potentially processed and presented on the surface of cancer cells and therefore recognized by the T cells, eliciting the anti-tumor response (41).”
BackgroundSpahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., Biskup, S., Feldhahn, M., Nahnsen, S., Hilke, F. J., et al. (2020) · Cancers · doi:10.3390/cancers12123830 · Cited by 79
“The median TMB of 2.6 Var/Mbp observed in our cohort was low when compared to other tumor entities that benefit from ICI treatment, especially melanoma, but was in a similar range in a recent study of 755 HCC cases in which the median TMB was 4 Var/Mbp and only 5% of patients had a TMB 10 Var/Mbp [36,37].”
BackgroundResultInfluentialManning‐Geist, B. L., Liu, Y. L., Devereaux, K. A., Paula, A. D. C., Zhou, Q. C., Ma, W., Selenica, P., Ceyhan‐Birsoy, O., Moukarzel, L. A., Hoang, T. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0713 · Cited by 83
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Magnes, T., Wagner, S. M., Kiem, D., Weiß, L., Rinnerthaler, G., Greil, R., & Melchardt, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094981 · Cited by 83
“showed that TMB is significantly correlated with the ORR to anti-PD-1 or anti-PD-L1 therapy [93].”
BackgroundCancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 80
Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad031 · Cited by 73
“Prior studies of PD-1 inhibitors suggest TMB as an 42–45 46 a separate cohort for this patient population was not included in this study.”
Collins, J. M., Redman, J. M., & Gulley, J. L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506332 · Cited by 82
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Kverneland, A. H., Chamberlain, C. A., Borch, T. H., Nielsen, M., Mørk, S. K., Kjeldsen, J. W., Lorentzen, C. L., Jørgensen, L. P., Riis, L. B., Yde, C. W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003499 · Cited by 77
Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update
Boukouris, A. E., Theochari, M., Stefanou, D. T., Papalambros, A., Felekouras, E. S., Gogas, H. J., & Ziogas, D. C. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103663 · Cited by 85
Reese, M., & Dhayat, S. A. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01149-4 · Cited by 88
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 84
“…efficacy in melanoma, anti-PD-1, anti-PD-L1 and/or anti-CTLA-4 has been integrated as part of standard therapy in cancers such Hodgkin’s lymphoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC) (Wu et al., 2019; Yarchoan, Hopkins, & Jaffee, 2017; Zhao, Zhao, & Zhao, 2020).”
BackgroundUpdate on prognostic and predictive biomarkers of breast cancer
Hou, Y., Peng, Y. S., & Li, Z. (2022) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2022.06.015 · Cited by 78
Sabbatino, F., Marra, A., Liguori, L., Scognamiglio, G., Fusciello, C., Botti, G., Ferrone, S., & Pepe, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0439-2 · Cited by 74
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 78
“Unfortunately, research on immunotherapy for BC has lagged behind due to its perceived lower immunogenicity [11].”
Pediatric high‐grade glioma: moving toward subtype‐specific multimodal therapy
Chatwin, H. V., Cruz, J. C., & Green, A. L. (2021) · FEBS Journal · doi:10.1111/febs.15739 · Cited by 77
Dousset, L., Poizeau, F., Robert, C., Mansard, S., Mortier, L., Caumont, C., Routier, É., Dupuy, A., Rouanet, J., Battistella, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00084 · Cited by 83
“Another study highlighted an exponential relationship between TMB and objective response rate to PD-1 inhibitors, but the correlation was analyzed across different types of cancers only.(42) This can be applied to individual patient care or counseling: although a high TMB should favor single anti–PD-1 immunotherapy, a…”
BackgroundZhan, M., Yu, X., Zhao, W., Peng, Y., Peng, S., Li, J., & Lu, L. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01226-3 · Cited by 74
“However, this therapeutic strategy is often inoperative for clinic patients [7].”
BackgroundMody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khoueiry, A. B., Hockenberry, A. J., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00510 · Cited by 84
“Tumors with large numbers of genomic mutations (having a high tumor mutational burden [TMB]) appear to be particularly susceptible to immune-checkpoint blockade therapy.(14,15) Similarly, programmed deathligand 1 (PD-L1) protein levels are partially predictive of the response to anti–PD-L1 therapies across numerous ca…”
BackgroundSelf-citationMicrofluidics guided by deep learning for cancer immunotherapy screening
Ao, Z., Cai, H., Wu, Z., Hu, L., Nunez, A., Zhou, Z., Liu, H., Bondesson, M., Lu, X., Lü, X., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214569119 · Cited by 78
“A large number of spheroids (7,680) per plate can be formed within pillar-lattice-arrays within one well; they reached their maximum diameter on day 3 and were arrested at uniform sizes (160 ± 9.”
BackgroundYang, Y., Liu, H., Chen, Y., Xiao, N., Zheng, Z., Liu, H., & Wan, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05757-5 · Cited by 78
“These mutations can lead to neoantigen formation, contribute to the immunogenicity of the tumor [44, 45], and improve the possibility of patient response to ICI treatment [46].”
BackgroundXu, P., Yang, J. C., Chen, B., Nip, C., Dyke, J. E. V., Zhang, X., Chen, H., Evans, C. P., Murphy, W. J., & Liu, C. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006581 · Cited by 80
Paulson, K. G., Lahman, M. C., Chapuis, A. G., & Brownell, I. (2019) · International Immunology · doi:10.1093/intimm/dxz012 · Cited by 75
Liquid biopsy in tumors: opportunities and challenges
Bai, Y., & Zhao, H. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.31 · Cited by 77
“concluded that there was a significant positive correlation between TMB and response rate of immunological checkpoint inhibitor treatment after analyzing multiple clinical study data (13).”
BackgroundTRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies
Dianat‐Moghadam, H., Heidarifard, M., Mahari, A., Shahgolzari, M., Keshavarz, M., Nouri, M., & Amoozgar, Z. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104716 · Cited by 70
Role of DNA repair defects in predicting immunotherapy response
Zhang, J., Shih, D. J. H., & Lin, S.-Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 69
Ma, C., Luo, H., Cao, J., Zheng, X., Zhang, J., Zhang, Y., & Fu, Z. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.571641 · Cited by 80
The evolving role of immune cells in prostate cancer
Wang, C., Zhang, Y., & Gao, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.027 · Cited by 81
PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
Sim, H., Galanis, E., & Khasraw, M. (2022) · Cancers · doi:10.3390/cancers14041003 · Cited by 71
“The efficacy of immune checkpoint inhibitors in highly mutated tumors has been well established [73].”
BackgroundKleinberg, L. R., Sloan, L., Grossman, S. A., & Lim, M. K. (2019) · Neurosurgery · doi:10.1093/neuros/nyz198 · Cited by 74
Salzmann, M., Leiter, U., Loquai, C., Zimmer, L., Ugurel, S., Gutzmer, R., Thoms, K., Enk, A., & Hassel, J. C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.029 · Cited by 72
Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy
Fenizia, F., Pasquale, R., Roma, C., Bergantino, F., Iannaccone, A., & Normanno, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.23 · Cited by 69
“TMB has newly emerged as a possible independent biomarker to predict patient responses to immunotherapy in different tumor types, including lung cancer (2,3,15-22).”
BackgroundZhang, Y., Jiang, X., Zhang, N., Chen, M., Wang, H., & Zhu, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.017 · Cited by 91
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Mao, W., Ghasemzadeh, A., Freeman, Z. T., Obradović, A., Chaimowitz, M. G., Nirschl, T. R., Emily, M., Yegnasubramanian, S., & Drake, C. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0758-y · Cited by 72
Smectite promotes probiotic biofilm formation in the gut for cancer immunotherapy
Han, C., Song, J., Hu, J., Fu, H., Feng, Y., Mu, R., Xing, Z., Wang, Z., Wang, L., Zhang, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108706 · Cited by 70
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
Lurain, K. A., Ramaswami, R., Mangusan, R., Widell, A., Ekwede, I., George, J. M., Ambinder, R. F., Cheever, M. A., Gulley, J. L., Goncalves, P. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002097 · Cited by 72
Pan-cancer analysis reveals molecular patterns associated with age
Shah, Y., Verma, A., Marderstein, A. R., White, J. B., Bhinder, B., Medina, J. S. G., & Elemento, O. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110100 · Cited by 88
Manca, P., Corti, F., Intini, R., Mazzoli, G., Miceli, R., Germani, M. M., Bergamo, F., Ambrosini, M., Cristarella, E., Cerantola, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.029 · Cited by 73
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Peyraud, F., Guégan, J., Vanhersecke, L., Brunet, M., Teyssonneau, D., Palmieri, L., Bessede, A., & Italiano, A. (2025) · Med · doi:10.1016/j.medj.2024.10.023 · Cited by 81
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 78
Nejo, T., Matsushita, H., Karasaki, T., Nomura, M., Saito, K., Tanaka, S., Takayanagi, S., Hana, T., Takahashi, S., Kitagawa, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0599 · Cited by 73
“Compared with melanomas or non–small cell lung cancers (NSCLC), the mutation/neoantigen burden is generally not high in glioma, with the exception of certain "hypermutators" (25, 47, 48).”
BackgroundHIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.046 · Cited by 68
Huemer, F., Lang, D., Westphal, T., Gampenrieder, S. P., Hutarew, G., Weiß, L., Hackl, H., Lamprecht, B., Rinnerthaler, G., & Greil, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071014 · Cited by 72
“Tumor mutational burden (TMB) represents another biomarker of interest to guide immune-checkpoint inhibitor therapy in various tumor entities [23].”
BackgroundToyoda, T., Kamata, T., Tanaka, K., Ihara, F., Takami, M., Suzuki, H., Nakajima, T., Ikeuchi, T., Kawasaki, Y., Hanaoka, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000316 · Cited by 72
Molecular pathology of urothelial carcinoma
Antonio Lopez-beltran, B., Cimadamore, A., Montironi, R., & Liang Cheng, C. (2021) · Human Pathology · doi:10.1016/j.humpath.2021.04.001 · Cited by 73
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
“Another example of the TMBlow cancer that responds well to immunotherapy due to tumor hERV expression, is Merkel cell carcinoma, a tumor linked to Merkel cell polyomavirus [22].”
BackgroundInfluentialKing, R. J., Shukla, S. K., He, C., Vernucci, E., Thakur, R., Attri, K. S., Dasgupta, A., Chaika, N. V., Mulder, S. E., Abrego, J., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02132-6 · Cited by 75
Muto, S., Enta, A., Maruya, Y., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010190 · Cited by 73
“Although not a perfect biomarker, because of the other steps of the cancer-immunity cycle, there is an association between the tumor mutational burden and a therapeutic response to immune checkpoint inhibitors [14,54].”
BackgroundKim, G. B., Nam, G.-H., Hong, Y., Woo, J., Cho, Y., Kwon, I. C., Yang, Y., & Kim, I.-S. (2020) · Science Advances · doi:10.1126/sciadv.aaz2083 · Cited by 62
“Accumulating evidence indicates that the response rate of cancer immunotherapy is often associated with the immunogenicity of a tumor, with tumors bearing high mutational burden showing more improved response to immune checkpoint inhibitor than tumors bearing low mutational burden (2).”
BackgroundEso, Y., & Seno, H. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820948773 · Cited by 72
Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors
Iwanowycz, S., Ngoi, S. M., Li, Y., Hill, M., Koivisto, C. S., Parrish, M., Guo, B., Li, Z., & Liu, B. (2021) · JCI Insight · doi:10.1172/jci.insight.145885 · Cited by 74
“Immunogenic tumors with a high mutation burden tend to interfere with end-stage T cell responses, thus requiring treatments that target checkpoints, such as PD-1 blockade therapy, in order to normalize immunity (2, 10, 11).”
BackgroundTargets of tumor microenvironment for potential drug development
Zhang, L., Wang, Z., Liu, K., Liu, Y., Wang, S., Jiang, W., Lu, F., & Dang, Y. (2024) · MedComm – Oncology · doi:10.1002/mog2.68 · Cited by 76
Gene code CD274/PD-L1 : from molecular basis toward cancer immunotherapy
Fabrizio, F. P., Trombetta, D., Rossi, A., Sparaneo, A., Castellana, S., & Muscarella, L. A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918815598 · Cited by 76
Cancer-on-chip models for metastasis: importance of the tumor microenvironment
Jouybar, M., de Winde, C. M., Wolf, K., Friedl, P., Mebius, R. E., & den Toonder, J. M. J. (2024) · Trends in Biotechnology · doi:10.1016/j.tibtech.2023.10.001 · Cited by 66
“…these studies are limited to particular cancer types and subsets of patients, to difference in mutation load seen in different cancer types, and immune-related adverse of therapy may occur [93 – 96]. of immune cells CoC models can help to determine how the antitumor immune response can be improved.”
BackgroundOyanagi, J., Koh, Y., Sato, K., Mori, K. P., Teraoka, S., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.020 · Cited by 73
Jacot, W., Lopez‐Crapez, E., Mollévi, C., Boissière‐Michot, F., Simony-Lafontaine, J., Ho-Pun-Cheung, A., Chartron, E., Theillet, C. G., Lemoine, A., Saffroy, R., et al. (2020) · Cancers · doi:10.3390/cancers12040828 · Cited by 74
“One of the key determinants of immunotherapy activity appears to be linked to the tumor mutational burden and genome instability [47].”
BackgroundEndometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance
Steinbuch, S. C., Lüß, A.-M., Eltrop, S., Götte, M., & Kiesel, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084306 · Cited by 80
“Additionally, the tumor mutation burden might predict the response to immunotherapy in EAOC [199], making it a potential biomarker for therapy susceptibility, as demonstrated in other tumors [200,201].”
BackgroundAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 80
Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma
Pires‐Afonso, Y., Niclou, S. P., & Michelucci, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030689 · Cited by 68
“However, as indicated above, this model poorly reflects human disease, since GBM patients typically show low mutational load and weak tumour immunogenicity, which correlates with poor response to immune checkpoint inhibitors [53].”
BackgroundHo, W. J., Danilova, L., Lim, S. J., Verma, R., Xavier, S., Leatherman, J. M., Sztein, M. B., Fertig, E. J., Wang, H., Jaffee, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000394 · Cited by 66
Self-citationZang, Y., Dai, C., Xu, X., Cai, X., Wang, G., Wei, J., Wu, A., Sun, W., Jiao, S., & Xu, Q. (2019) · Cancer Medicine · doi:10.1002/cam4.2381 · Cited by 78
Passaro, A., Attili, I., Morganti, S., Signore, E. D., Gianoncelli, L., Spitaleri, G., Stati, V., Catania, C., Curigliano, G., & de Marinis, F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102085 · Cited by 84
Chemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine
Gmeiner, W. H. (2020) · Molecules · doi:10.3390/molecules25153438 · Cited by 66
“Increased mutagenicity has implications for use in cancer treatment [66], including immunotherapy applications, which are affected by overall tumor mutational burden [67].”
BackgroundImmune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Aziz, M. A. A. E., Facciorusso, A., Nayfeh, T., Saadi, S. M., Elnaggar, M. Y., Cotsoglou, C., & Sacco, R. (2020) · Vaccines · doi:10.3390/vaccines8040616 · Cited by 67
Nersesjan, V., McWilliam, O. H., Krarup, L.-H., & Kondziella, D. (2021) · Neurology · doi:10.1212/wnl.0000000000012122 · Cited by 75
Chen, F., Yang, J., Fang, M., Wu, Y., Su, D., & Sheng, Y. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24302 · Cited by 80
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 78
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 69
“TMB has emerged as another potential biomarker, with higher mutational burden generally associated with improved ICI ef fi cacy, as supported by a retrospective analysis of 27 tumor types (181).”
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.